Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

Outcomes With Idelalisib Differ in the Clinical Trial Versus Real-World Setting

According to a real-world analysis published in JAMA Oncology, treatment outcomes with idelalisib differed between patients with follicular lymphoma (FL) and chronic lymphocytic leukemia...

DDGP Versus SMILE: Comparing Regimens for Extranodal Natural Killer T-Cell Lymphoma

In patients with extranodal natural killer T-cell lymphoma (ENKTL), treatment with the chemotherapy regimen of dexamethasone, cisplatin, gemcitabine, and pegasparaginase (DDGP) improved survival compared...
You Make the Call

You Make the Call: What is the best consolidation therapy for this patient with...

This month, Erin Reid, MD, discusses treatment of primary central nervous system lymphoma. And don't forget to check out next month's clinical dilemma - send...
How I Treat In Brief

How I Treat in Brief: Early Relapsing Follicular Lymphoma

Carla Casulo, MD, and Paul M. Barr, MD, from the Wilmot Cancer Institute at the University of Rochester Medical Center in New York, reviewed...

Treatment With Four Cycles of R-CHOP Is Non-Inferior to Six Cycles in Some Aggressive...

For patients with aggressive B-cell non-Hodgkin lymphoma (NHL) and a favorable prognosis, treatment with four cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and...

HHS Allows Novartis to Pay Travel Expenses for Tisagenlecleucel Patients

The U.S. Department of Health and Human Services (HHS) will allow Novartis to cover travel, lodging, and meal expenses for Medicaid and Medicare beneficiaries...

CS1001 Shows High Response Rate in Extranodal Natural Killer T-Cell Lymphoma

According to early phase II trial data, the investigational immunotherapy CS1001 shows anti-tumor activity against relapsed/refractory extranodal natural killer T-cell lymphoma (ENKTL). The results...

Treatment for Lymphoplasmacytic Lymphoma Receives Orphan Designation

The FDA granted orphan drug designation to CLR 131, a phospholipid-drug conjugate that selectively delivers the radioisotope iodine-131 to tumor cells. CLR 131 is being...

FDA Places Partial Hold on Clinical Trials of Lacutamab for Advanced T-Cell Lymphomas

The FDA has placed a partial clinical hold on the phase II TELLOMAK trial, which is evaluating the safety and efficacy of lacutamab in...
WIB_icon

Updates From ECHELON-1: Brentuximab Vedotin Provides Durable Efficacy in Hodgkin Lymphoma

Previously reported results from the phase III ECHELON-1 trial suggested that replacing bleomycin with brentuximab vedotin in the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)...
Advertisement

Current Issue

August 2020 Volume 6, Issue 10

This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.

Block title